dr. nicholas vogelzang on first-line axitinib versus sorafenib in mrcc
Published 11 years ago • 90 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
11:26
axis trial: second-line axitinib versus sorafenib in metastatic renal cell carcinoma
-
0:43
dr. rini on the results from his axitinib and sorafenib trial
-
3:57
agile trial: frontline axitinib versus sorafenib in metastatic renal cell carcinoma
-
1:12
dr. rini describes axitinib's and sorafenib's side effects
-
1:53
dr. nicholas vogelzang discusses sequencing abiraterone and enzalutamide
-
3:25
evolving renal cell carcinoma treatment paradigm
-
2:11
dr. cella discusses axitinib and sorafenib axis trial
-
1:40
mitochondria: a primer
-
1:04
dr. figlin on intermediate prognosis patients with mrcc
-
2:25
dr. motzer on a phase ii trial of nivolumab for mrcc
-
7:49
immunotherapeutic combinations for mrcc: immotion-151
-
2:12
phase 1 study of anti-pd-l1 durvalumab plus gefitinib in tki-naïve patients with egfr-mutant nsclc
-
5:27
latest news & insight: october 31, 2014
-
3:29
other emerging combination approaches in rcc
-
2:22
keynote-057: extended follow-up of pembrolizumab in bladder cancer
-
2:50
nivolumab and allogeneic transplantation in r/r classical hodgkin lymphoma
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
0:35
nobel prize in medicine honors pioneering research that helps fight disease
-
1:59
dr. daisuke okuzaki - single cell analysis for human immunology research -